New hope for glioblastoma: phase 3 trial pits niraparib against standard chemo
Disease control
Ongoing
This Phase 3 trial compares the drug niraparib to the standard chemo temozolomide in 450 adults with newly diagnosed, aggressive glioblastoma that has a specific genetic marker (MGMT unmethylated). Participants take the assigned drug daily during radiation, then continue until th…
Phase: PHASE3 • Sponsor: Ivy Brain Tumor Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC